Loading...

Douglas Goodin, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentNeurology
Address675 Nelson Rising Lane
San Francisco CA 94158
Phone415-514-2464
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine - Neurology

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Goodin D, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2018 May 01; 1352458518773511. PMID: 29761737.
      View in: PubMed
    2. Goodin D, Mitsikostas DD. Reply to Tsivgoulis and colleagues comments. Mult Scler Relat Disord. 2018 Apr; 21:120-121. PMID: 29724376.
      View in: PubMed
    3. Goodin D, Khankhanian P, Gourraud PA, Vince N. Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility. PLoS One. 2018; 13(2):e0190043. PMID: 29438392.
      View in: PubMed
    4. Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin D, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA. Harnessing electronic medical records to advance research on multiple sclerosis. Mult Scler. 2018 Jan 01; 1352458517747407. PMID: 29310490.
      View in: PubMed
    5. Mitsikostas DD, Goodin D. Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Mult Scler Relat Disord. 2017 Nov; 18:109-116. PMID: 29141791.
      View in: PubMed
    6. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016 Oct; 80(4):499-510. PMID: 27464262.
      View in: PubMed
    7. Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung HP, Comi G, Jeffery DR, Kappos L, Goodin D, Arnason B. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016 Jul; 263(7):1418-26. PMID: 27177997; PMCID: PMC4929160.
    8. Goodin D. The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities. BMC Neurol. 2016 Apr 27; 16:56. PMID: 27117889; PMCID: PMC4847201.
    9. Goodin D. The epidemiology of multiple sclerosis: insights to a causal cascade. Handb Clin Neurol. 2016; 138:173-206. PMID: 27637959.
      View in: PubMed
    10. Fitzgerald KC, Munger KL, Köchert K, Arnason BG, Comi G, Cook S, Goodin D, Filippi M, Hartung HP, Jeffery DR, O'Connor P, Suarez G, Sandbrink R, Kappos L, Pohl C, Ascherio A. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015 Dec; 72(12):1458-65. PMID: 26458124.
      View in: PubMed
    11. Collins CD, Ivry B, Bowen JD, Cheng EM, Dobson R, Goodin D, Lechner-Scott J, Kappos L, Galea I. A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. Mult Scler. 2016 09; 22(10):1349-58. PMID: 26564998; PMCID: PMC5015760.
    12. Goodin D, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E. Relapses in multiple sclerosis: Relationship to disability. Mult Scler Relat Disord. 2016 Mar; 6:10-20. PMID: 27063617.
      View in: PubMed
    13. Hartung HP, Kappos L, Goodin D, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. J Neurol. 2015 Nov; 262(11):2466-71. PMID: 26239222; PMCID: PMC4639578.
    14. Schlaeger R, Papinutto N, Zhu AH, Lobach IV, Bevan CJ, Bucci M, Castellano A, Gelfand JM, Graves JS, Green AJ, Jordan KM, Keshavan A, Panara V, Stern WA, von Büdingen HC, Waubant E, Goodin D, Cree BA, Hauser SL, Henry RG. Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurol. 2015 Aug; 72(8):897-904. PMID: 26053119.
      View in: PubMed
    15. Khankhanian P, Gourraud PA, Lizee A, Goodin D. Haplotype-based approach to known MS-associated regions increases the amount of explained risk. J Med Genet. 2015 Sep; 52(9):587-94. PMID: 26185143; PMCID: PMC4552900.
    16. Wilson LS, Loucks A, Gipson G, Zhong L, Bui C, Miller E, Owen M, Pelletier D, Goodin D, Waubant E, McCulloch CE. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015 Mar-Apr; 17(2):74-82. PMID: 25892977; PMCID: PMC4399770.
    17. Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin D, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL. Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol. 2014 Nov; 76(5):633-42. PMID: 25263997; PMCID: PMC4214886.
    18. Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von Büdingen HC, Waubant E, Zhu AH, Goodin D, Cree BA, Hauser SL, Henry RG. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014 Oct; 76(4):568-80. PMID: 25087920.
      View in: PubMed
    19. Goodin D, Corwin M, Kaufman D, Golub H, Reshef S, Rametta MJ, Knappertz V, Cutter G, Pleimes D. Causes of death among commercially insured multiple sclerosis patients in the United States. PLoS One. 2014; 9(8):e105207. PMID: 25144226; PMCID: PMC4140735.
    20. Wilson L, Loucks A, Bui C, Gipson G, Zhong L, Schwartzburg A, Crabtree E, Goodin D, Waubant E, McCulloch C. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci. 2014 Sep 15; 344(1-2):80-7. PMID: 25037284.
      View in: PubMed
    21. Goodin D, Khankhanian P. Single nucleotide polymorphism (SNP)-strings: an alternative method for assessing genetic associations. PLoS One. 2014; 9(4):e90034. PMID: 24727690; PMCID: PMC3984082.
    22. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56. PMID: 24685276.
      View in: PubMed
    23. Goodin D. Glucocorticoid treatment of multiple sclerosis. Handb Clin Neurol. 2014; 122:455-64. PMID: 24507531.
      View in: PubMed
    24. Goodin D. Preface. Handb Clin Neurol. 2014; 122:ix-x. PMID: 24507541.
      View in: PubMed
    25. Goodin D. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014; 122:231-66. PMID: 24507521.
      View in: PubMed
    26. Hartung HP, Steinman L, Goodin D, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C. Interleukin 17F level and interferon ß response in patients with multiple sclerosis. JAMA Neurol. 2013 Aug; 70(8):1017-21. PMID: 23732754; PMCID: PMC4290836.
    27. Scalfari A, Knappertz V, Cutter G, Goodin D, Ashton R, Ebers GC. Mortality in patients with multiple sclerosis. Neurology. 2013 Jul 09; 81(2):184-92. PMID: 23836941; PMCID: PMC3770174.
    28. Goodin D. The use of interferon Beta and glatiramer acetate in multiple sclerosis. Semin Neurol. 2013 Feb; 33(1):13-25. PMID: 23709209.
      View in: PubMed
    29. Goodin D. The genetic and environmental bases of complex human-disease: extending the utility of twin-studies. PLoS One. 2012; 7(12):e47875. PMID: 23272039; PMCID: PMC3525648.
    30. Goodin D, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNß-1b study. BMJ Open. 2012; 2(6). PMID: 23204140; PMCID: PMC3533062.
    31. Goodin D, Reder AT. Response to GS Gronseth and E Ashman. Mult Scler. 2012 Nov; 18(11):1661-2; author reply 1663-4. PMID: 23100528.
      View in: PubMed
    32. Goodin D, Reder AT, Cutter G. Treatment with interferon beta for multiple sclerosis. JAMA. 2012 Oct 24; 308(16):1627; author reply 1627-8. PMID: 23093155.
      View in: PubMed
    33. Goodin D, Reder AT. Evidence-based medicine: promise and pitfalls. Mult Scler. 2012 Jul; 18(7):947-8. PMID: 22740607.
      View in: PubMed
    34. Hartung HP, Kieseier B, Goodin D, Arnason BG, Comi G, Cook S, Filippi M, Jeffery DR, Kappos L, Bogumil T, Stemper B, Sandbrink R, Nakada Y, Nakajima H, Schwenke S, Lehr S, Heubach J, Pohl C, Reischl J. Variability in detection and quantification of interferon ß-1b-induced neutralizing antibodies. J Neuroinflammation. 2012 Jun 15; 9:129. PMID: 22703536; PMCID: PMC3403940.
    35. Marcus JF, Goodin D, Harris CA, Josephson SA. Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring-reply. Arch Neurol. 2012 Jun 01; 69(6):793-4. PMID: 23753930.
      View in: PubMed
    36. Gelfand JM, Goodin D, Boscardin WJ, Nolan R, Cuneo A, Green AJ. Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PLoS One. 2012; 7(5):e36847. PMID: 22666330; PMCID: PMC3359324.
    37. Goodin D, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNß-1b trial. Neurology. 2012 Apr 24; 78(17):1315-22. PMID: 22496198; PMCID: PMC3335454.
    38. Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin D, Armon C, Chaudhry V, Gronseth GS, Harden CL. Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials*. J Clin Neurophysiol. 2012 Feb; 29(1):101-8. PMID: 22353994.
      View in: PubMed
    39. Marcus JF, Shalev SM, Harris CA, Goodin D, Josephson SA. Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution. Arch Neurol. 2012 Jan; 69(1):129-32. PMID: 22232355.
      View in: PubMed
    40. Goodin D, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ß-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-7. PMID: 22193561.
      View in: PubMed
    41. Patsopoulos NA. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912. PMID: 22190364; PMCID: PMC3247076.
    42. Goodin D, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011; 6(11):e22444. PMID: 22140424.
      View in: PubMed
    43. Goodin D. Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous road. Mult Scler. 2011 Nov; 17(11):1274-5. PMID: 22058084.
      View in: PubMed
    44. Goodin D, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler. 2012 Feb; 18(2):181-95. PMID: 21952094.
      View in: PubMed
    45. Goodin D. Multiple Sclerosis: The Big Questions- The MS Forum Workshop. Int MS J. 2011 Sep; 17(3):100-7. PMID: 21689494.
      View in: PubMed
    46. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin D, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011 Feb 03; 6(2):e16664. PMID: 21304907; PMCID: PMC3033401.
    47. Goodin D. The genetic basis of multiple sclerosis: a model for MS susceptibility. BMC Neurol. 2010 Oct 28; 10:101. PMID: 21029420; PMCID: PMC2994805.
    48. Cree BA, Kornyeyeva E, Goodin D. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug; 68(2):145-50. PMID: 20695007.
      View in: PubMed
    49. Goodin D, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009 Oct; 15(10):1175-82. PMID: 19737851.
      View in: PubMed
    50. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10):889-97. PMID: 19729344.
      View in: PubMed
    51. Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin D, Wolf C, Beckmann K, Konieczny A. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug; 31(8):1724-36. PMID: 19808131.
      View in: PubMed
    52. Tien I, Glaser SD, Bajcsy R, Goodin D, Aminoff MJ. Results of using a wireless inertial measuring system to quantify gait motions in control subjects. IEEE Trans Inf Technol Biomed. 2010 Jul; 14(4):904-15. PMID: 19423449.
      View in: PubMed
    53. Arnold DL, Goodin D. Magnetic resonance imaging as a surrogate for treatment effect on multiple sclerosis relapses. Ann Neurol. 2009 Mar; 65(3):237-8. PMID: 19334057.
      View in: PubMed
    54. Goodin D. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One. 2009; 4(2):e4565. PMID: 19242548; PMCID: PMC2644781.
    55. Goodin D. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology. 2008 Dec 09; 71(24 Suppl 3):S8-13. PMID: 19064873.
      View in: PubMed
    56. Ralph JW, Goodin D, Long JM, Aminoff MJ. Electrical brain events associated with awareness of errors. Brain Res. 2009 Jan 28; 1251:213-22. PMID: 19046953.
      View in: PubMed
    57. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin D, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009 Feb 15; 18(4):767-78. PMID: 19010793; PMCID: PMC4334814.
    58. Goodin D. The impact of war-stress on MS exacerbations. Ann Neurol. 2008 Aug; 64(2):114-5. PMID: 18626947.
      View in: PubMed
    59. Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Clin Ther. 2008 Jun; 30(6):1102-12. PMID: 18640466.
      View in: PubMed
    60. Aminoff MJ, Goodin D. Electrophysiological evaluation of dementia. Handb Clin Neurol. 2008; 89:63-74. PMID: 18631731.
      View in: PubMed
    61. Goodin D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Karussis D, Miller A, Pakdaman H, Selmaj K, Sharief M. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Curr Med Res Opin. 2007 Nov; 23(11):2823-32. PMID: 17908370.
      View in: PubMed
    62. Goodin D, Hurwitz B, Noronha A. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res. 2007 Mar-Apr; 35(2):173-87. PMID: 17542405.
      View in: PubMed
    63. Goodin D. Age at disability milestones in multiple sclerosis and history of multiple sclerosis: a unifying concept. Brain. 2006 Dec; 129(Pt 12):e56; author reply e57. PMID: 17132635.
      View in: PubMed
    64. Goodin D. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology. 2006 Oct 10; 67(7):1313-4. PMID: 17030783.
      View in: PubMed
    65. Goodin D. The use of MRI in the diagnosis of multiple sclerosis. Lancet Neurol. 2006 Oct; 5(10):808-9. PMID: 16987725.
      View in: PubMed
    66. Goodin D. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006 Sep 26; 67(6):1104; author reply 1104-5. PMID: 17000997.
      View in: PubMed
    67. Goodin D. The return of natalizumab: weighing benefit against risk. Lancet Neurol. 2006 May; 5(5):375-7. PMID: 16632301.
      View in: PubMed
    68. Goodin D. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol. 2006 Apr; 59(4):597-605. PMID: 16566022.
      View in: PubMed
    69. Goodin D, Frohman EM. Overdiagnosis of multiple sclerosis by magnetic resonance imaging. Ann Neurol. 2006 Mar; 59(3):575-6; author reply 576. PMID: 16489616.
      View in: PubMed
    70. Cree BA, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol. 2005 Nov; 62(11):1681-3. PMID: 16286540.
      View in: PubMed
    71. Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci. 2005 Dec 15; 239(1):67-74. PMID: 16169561.
      View in: PubMed
    72. Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol. 2005 May; 62(5):785-92. PMID: 15883267.
      View in: PubMed
    73. Goodin D. Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-response. J Neurol. 2004 Sep; 251 Suppl 5:v50-v56. PMID: 15549356.
      View in: PubMed
    74. Goodin D. Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors. J Neurol. 2004 Sep; 251 Suppl 5:v3-v11. PMID: 15549352.
      View in: PubMed
    75. Goodin D. Relationship between multiple sclerosis exacerbations and stress. Psychosom Med. 2004 Mar-Apr; 66(2):287-9; author reply 287-9. PMID: 15039517.
      View in: PubMed
    76. Goodin D. Marijuana and multiple sclerosis. Lancet Neurol. 2004 Feb; 3(2):79-80. PMID: 14746994.
      View in: PubMed
    77. Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L, Goodin D, Erlich HA, Schmidt S, Thomson G, Reich DE, Pericak-Vance MA, Haines JL, Hauser SL. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet. 2004 Jan; 74(1):160-7. PMID: 14669136; PMCID: PMC1181903.
    78. Leppert D, Goodin D, Aminoff MJ. Stimulus recognition and its relationship to the cerebral event-related potential. Neurology. 2003 Dec 09; 61(11):1533-7. PMID: 14663038.
      View in: PubMed
    79. Goodin D. Interferons in relapsing remitting multiple sclerosis. Lancet. 2003 May 24; 361(9371):1821; author reply 1823-4. PMID: 12781556.
      View in: PubMed
    80. Corboy JR, Goodin D, Frohman EM. Disease-modifying Therapies for Multiple Sclerosis. Curr Treat Options Neurol. 2003 Jan; 5(1):35-54. PMID: 12521562.
      View in: PubMed
    81. Cree BA, Goodin D, Hauser SL. Neuromyelitis optica. Semin Neurol. 2002 Jun; 22(2):105-22. PMID: 12524556.
      View in: PubMed